Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In vivo binding and antitumor activity of Ch14.18.
Kendra K, Malkovska V, Allen M, Guzman J, Albertini M. Kendra K, et al. J Immunother. 1999 Sep;22(5):423-30. doi: 10.1097/00002371-199909000-00006. J Immunother. 1999. PMID: 10546158
Correction: Association between pre‑treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis.
Wong A, Riley M, Zhao S, Wang JG, Esguerra V, Li M, Lopez G, Otterson GA, Kendra K, Presley CJ, Wei L, Owen DH, Ho K. Wong A, et al. Among authors: kendra k. Cancer Immunol Immunother. 2023 Jun;72(6):1737. doi: 10.1007/s00262-023-03391-w. Cancer Immunol Immunother. 2023. PMID: 36806904 Free PMC article. No abstract available.
Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis.
Wong A, Riley M, Zhao S, Wang JG, Esguerra V, Li M, Lopez G, Otterson GA, Kendra K, Presley CJ, Wei L, Owen DH, Ho K. Wong A, et al. Among authors: kendra k. Cancer Immunol Immunother. 2023 Jun;72(6):1727-1735. doi: 10.1007/s00262-023-03373-y. Epub 2023 Jan 14. Cancer Immunol Immunother. 2023. PMID: 36640189 Free PMC article.
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.
Unger JM, Darke A, Othus M, Truong TG, Khushalani N, Kendra K, Lewis KD, Faller B, Funchain P, Buchbinder EI, Tarhini AA, Kirkwood JM, Sharon E, Sondak V, Guild SR, Grossmann K, Ribas A, Patel SP. Unger JM, et al. Among authors: kendra k. JAMA Oncol. 2023 Feb 1;9(2):251-260. doi: 10.1001/jamaoncol.2022.5486. JAMA Oncol. 2023. PMID: 36416836 Free PMC article. Clinical Trial.
Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer.
Wong A, Riley M, Zhao S, Zimmer J, Viveiros M, Wang JG, Esguerra V, Li M, Lopez G, Kendra K, Carbone DP, He K, Alahmadi A, Kaufman J, Memmott RM, Shields PG, Brownstein J, Haglund K, Welliver M, Otterson GA, Presley CJ, Wei L, Owen DH, Ho K. Wong A, et al. Among authors: kendra k. J Natl Compr Canc Netw. 2023 Nov;21(11):1164-1171.e5. doi: 10.6004/jnccn.2023.7059. J Natl Compr Canc Netw. 2023. PMID: 37935100
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators. Weber J, et al. N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10. N Engl J Med. 2017. PMID: 28891423 Free article. Clinical Trial.
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.
VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, Kuklinski LF, Collichio F, Sosman JA, Ikeguchi A, Victor AI, Truong TG, Chmielowski B, Portnoy DC, Chen Y, Margolin K, Bane C, Dasanu CA, Johnson DB, Eroglu Z, Chandra S, Medina E, Gonzalez CR, Baselga-Carretero I, Vega-Crespo A, Garcilazo IP, Sharon E, Hu-Lieskovan S, Patel SP, Grossmann KF, Moon J, Wu MC, Ribas A. VanderWalde A, et al. Among authors: kendra kl. Nat Med. 2023 Sep;29(9):2278-2285. doi: 10.1038/s41591-023-02498-y. Epub 2023 Aug 17. Nat Med. 2023. PMID: 37592104 Free PMC article. Clinical Trial.
BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy.
Sun SH, Angell CD, Savardekar H, Sundi D, Abood D, Benner B, DiVincenzo MJ, Duggan M, Choueiry F, Mace T, Trikha P, Lapurga G, Johnson C, Carlson EJ, Chung C, Peterson BR, Lianbo Yu, Zhao J, Kendra KL, Carson WE 3rd. Sun SH, et al. Among authors: kendra kl. Cancer Immunol Immunother. 2023 Nov;72(11):3461-3474. doi: 10.1007/s00262-023-03497-1. Epub 2023 Aug 2. Cancer Immunol Immunother. 2023. PMID: 37528320 Free PMC article.
Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase.
Savardekar H, Allen C, Jeon H, Li J, Quiroga D, Schwarz E, Wu RC, Zelinskas S, Lapurga G, Abreo A, Stiff A, Shaffer J, Blaser BW, Old M, Wesolowski R, Xin G, Kendra KL, Chung D, Carson WE 3rd. Savardekar H, et al. Among authors: kendra kl. Mol Cancer Res. 2024 Mar 1;22(3):308-321. doi: 10.1158/1541-7786.MCR-22-0572. Mol Cancer Res. 2024. PMID: 38015751
105 results